Cancer test maker Grail starts trading after spin-off from Illumina

Grail

25/06/2024 14:34

June 25 (Reuters) - Shares of cancer diagnostic test
maker Grail  GRAL.O  began trading at $18.35 in their Nasdaq
debut on Tuesday after being spun off from gene-sequencing firm
Illumina  ILMN.O . 
        
  

 (Reporting by Pratik Jain and Arasu Kannagi Basil in Bengaluru;
Editing by Devika Syamnath)
 ((Pratik.Jain@thomsonreuters.com;))